| Molecule | Cat. No. | Product Name | Espèce | Host | Structure | Purity | Activity | Size&Price | Add to Cart |
|---|---|---|---|---|---|---|---|---|---|
| P-Selectin | Human P-Selectin / CD62P Protein, Fc Tag | Human | HEK293 | ![]() | SDS-PAGE | $270.00 100ug | |||
| P-Selectin | Human P-Selectin / CD62P Protein, His Tag | Human | HEK293 | ![]() | SDS-PAGE | $285.00 100ug |
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| Inclacumab | DSM-ACC-2641; RO 4905417; LC1004-002; DSM ACC2641; RG-1512; LC-1004-002; R-1512; PF-07940370; RO-4905417 | Phase 3 Clinical | F. Hoffmann-La Roche Ltd, Genmab A/S | Anemia, Sickle Cell; Graft Occlusion, Vascular; Myocardial Infarction; Pain; Peripheral Arterial Disease | Details |
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Plus ancien nom de marque | Pays d'approbation le plus ancien | Indication la plus ancienne | Société d'approbation la plus ancienne | Date d'approbation la plus ancienne | Indication | Essai clinique |
|---|---|---|---|---|---|---|---|---|---|---|
| Crizanlizumab | Sel-G-1; SEG-101; SEG101; Sel-G1 | Approved | Selexys Pharmaceuticals Corp | Adakveo, Ryverna | United States | Anemia, Sickle Cell | Novartis Pharmaceuticals Corp | 2019-11-15 | Anemia, Sickle Cell; Coronavirus Disease 2019 (COVID-19); Leukoencephalopathies; Priapism; Primary Myelofibrosis | Details |
